Search

The administration of sorbents plays a vital role in reducing systemic toxicity after radionuclides or harmful chemicals enter the organism. This study explores the pharmacological characteristics of the newly developed ferrocyanide-bentonite sorbent, Ferbensorb. As a composite formulation, Ferbensorb integrates potassium-iron(III) hexacyanoferrate(II), bentonite, gelatin, along with a mixture of essential macro- and microelements. Experimental assessments were performed using mice and rats as animal models. The investigation evaluated its cesium sorption efficacy, strontium radionuclide retention capability, and performance under simulated associative mycotoxicosis. Autopsies were conducted to assess anatomical alterations, while variations in overall body mass and the condition of specific internal organs were documented. Blood analyses also included profiling of the leukocyte formula. The findings demonstrated that the ferrocyanide-bentonite sorbent, Ferbensorb, effectively alleviated both structural and functional disruptions induced by mycotoxins, including ochratoxin A, fumonisin B, and zearalenone. Improvements were observed in weight gain, innate immune response (indicated by a higher proportion of neutrophils), enhanced serum lysozyme and bactericidal activities, and increased survival rates in the treated animals.